相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial
Michael L. Wang et al.
LANCET ONCOLOGY (2022)
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
Yuqin Song et al.
BLOOD (2022)
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Mantle-Cell Lymphoma
James O. Armitage et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
Martin Dreyling et al.
BLOOD (2022)
Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up
Martin Dreyling et al.
HEMASPHERE (2022)
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
Michael Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials
Keshu Zhou et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Anthony R Mato et al.
LANCET (2021)
SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK
U. Novak et al.
HEMATOLOGICAL ONCOLOGY (2021)
The combination of venetoclax, lenalidomide, and rituximab in patients with newly diagnosed mantle cell lymphoma induces high response rates and MRD undetectability.
Tycel Jovelle Phillips et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
p53 is associated with high-risk and pinpointsTP53missense mutations in mantle cell lymphoma
Joana M. Rodrigues et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management
Preetesh Jain et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
Michael Wang et al.
LEUKEMIA (2019)
Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study
Sasanka M. Handunnetti et al.
BLOOD (2019)
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis
Simon Rule et al.
HAEMATOLOGICA (2019)
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Constantine S. Tam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
Tadeusz Robak et al.
LANCET ONCOLOGY (2018)
Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network
Sietse M. Aukema et al.
BLOOD (2018)
SAKK 36/13-IBRUTINIB AND BORTEZOMIB FOLLOWED BY IBRUTINIB MAINTENANCE IN PATIENTS WITH RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: PHASE I REPORT OF A PHASE I/II TRIAL
U. Novak et al.
HEMATOLOGICAL ONCOLOGY (2017)
Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials
Ronald L. Van Heertum et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies
Simon Rule et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
Christian W. Eskelund et al.
BLOOD (2017)
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib
Girija Dasmahapatra et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
John Gerecitano et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status
P Perez-Galan et al.
BLOOD (2006)
分享论文
